PTC Unveils Arena SCI for Resilient Product Development
SCI is part of PTC's broader commitment to transforming the product development landscape through cloud-native solutions. Arena's integration with Onshape, PTC's cloud-native computer-aided design (CAD) and product data management (PDM) platform, has already laid the foundation for seamless cross-functional collaboration. With Arena SCI, PTC now offers the industry's first cloud-native CAD-PDM-PLM-Supply Chain solution, minimizing the usual challenges, expenses and custom coding required to link design and development systems.Recently, the company introduced model-based definition (MBD) capabilities within its Onshape platform—a fully cloud-native CAD and PDM solution. This initiative marks the first MBD offering of its kind in a cloud-native environment, designed to streamline product development by embedding product manufacturing information (PMI) directly into 3D models.
Since being acquired by PTC, Arena has accelerated its product roadmap with more than 16 major product releases, expansion into new global markets and collaboration with dozens of new ecosystem partners. It is trusted by nearly 1,500 global manufacturers, including Nutanix, Insulet, and Enphase Energy. With Arena SCI, PTC is solidifying its position as a digital transformation leader empowering customers to navigate complex, multi-tiered supply chains with ease.As global supply chains continue to evolve, tools like Arena SCI not only mitigate risk but also seize opportunity in a competitive, fast-moving marketplace.Nonetheless, PTC's frequent acquisitions have heightened its integration risks and negatively impacted its balance sheet. As of March 31, 2025, goodwill and acquired intangible assets totaled about $4.3 billion—roughly 70% of its total assets—highlighting the financial strain from acquisitions. These deals have also increased PTC's debt load, raising its overall risk exposure. At the end of the period, the company held $235 million in cash and cash equivalents, while total debt (net of deferred issuance costs) was $1.39 billion. PTC's debt-to-capital ratio is 0.29, notably higher than the industry average of 0.19, signaling elevated financial risk. This underscores the need for PTC to consistently generate sufficient cash flows to cover its debt obligations.
PTC currently carries a Zacks Rank #2 (Buy). Shares of the company have declined 6.6% in the past year against the Zacks Computer-Software industry's growth of 13.8%.
Image Source: Zacks Investment Research
Some other top-ranked stocks from the broader technology space are Juniper Networks, Inc. JNPR, Arista Networks, Inc. ANET and Ubiquiti Inc. UI. JNPR presently sports a Zacks Rank #1 (Strong Buy), while ANET and UI carry a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here.
Juniper is leveraging the 400-gig cycle to capture hyperscale switching opportunities inside the data center. The company is set to capitalize on the increasing demand for data center virtualization, cloud computing and mobile traffic packet/optical convergence. Juniper also introduced new features within the AI-driven enterprise portfolio that enable customers to simplify the rollout of their campus wired and wireless networks while bringing greater insight to network operators. In the last reported quarter, it delivered an earnings surprise of 4.88%.Arista delivered a trailing four-quarter average earnings surprise of 11.82% and has a long-term growth expectation of 14.81%. Arista currently serves five verticals, namely cloud titans (customers that deploy more than 1 million servers, cloud specialty providers, service providers, financial services and the rest of the enterprise. It supplies products to a prestigious set of customers, including Fortune 500 global companies in markets such as cloud titans, enterprises, financials and specialty cloud service providers.Ubiquiti's effective management of its strong global network of more than 100 distributors and master resellers improved its visibility for future demand and inventory management techniques. In the last reported quarter, Ubiquiti delivered an earnings surprise of 33.3%. Its highly flexible global business model remains well-suited to adapt to the changing market dynamics to overcome challenges while maximizing growth.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Juniper Networks, Inc. (JNPR) : Free Stock Analysis Report
Arista Networks, Inc. (ANET) : Free Stock Analysis Report
PTC Inc. (PTC) : Free Stock Analysis Report
Ubiquiti Inc. (UI) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Jon Ledecky, Carolyn Tisch Blodgett on ‘Sportico Sports Business'
Jon Ledecky, the New York Islanders co-owner and alternate team governor, emphasizes on the latest episode of Sportico Sports Business Presented by Genius Sports how his team's UBS Arena, which opened in 2021, is 'built for hockey, made for music.' While the Islanders are the arena's primary tenant, welcoming other performers and shows helps pay the bills. Ledecky says the Islanders' ownership group, which largely funded the construction of the arena, paid $100 million to make sure the acoustics were ideal for performers, not just a hockey game. More from Fenway Park Concession Workers Strike as Red Sox Host Dodgers Sporticast 468: What Is Gotham? Batman's Home, or New York City? Holy Trademark, Batman! Jets Claim on Gotham Denied by U.S. Gov The Islanders finished the 2024-25 season with a 35-35-12 record. The team won the 2025 NHL Draft lottery with just a 3.5% chance of doing so and selected 17-year-old Matthew Schaefer out of the Ontario Hockey League with the No. 1 pick. The Islanders opens their regular season on the road against the Pittsburgh Penguins on Oct. 9. They will host the Philadelphia Flyers in their first home game on Oct. 11. Also featured on the episode is Carolyn Tisch Blodgett, an operating owner and the club governor of the NWSL's Gotham FC. Tisch Blodgett, who has spent a lifetime in sports as part of the New York Giants' ownership group, doesn't shy away from the rising tides of women's soccer, both within the NWSL and around the world. She points to Angel City FC, the most valuable team in the NWSL, and Kansas City, which recently built a women-specific soccer stadium, as two teams elevating the game. 'We see competition within the league and outside of the league as very much continuing to raise the bar,' Tisch Blodgett said. 'If Chelsea competing for a player or Arsenal competing for a player continues to raise our bar, we think that's great for women's soccer globally.' Gotham currently has a 5-3-5 record for the 2025 season. Sportico Sports Business Presented by Genius Sports airs monthly on the YES Network and the Gotham Sports App. Best of Most Expensive Sports Memorabilia and Collectibles in History The 100 Most Valuable Sports Teams in the World NFL Private Equity Ownership Rules: PE Can Now Own Stakes in Teams
Business Wire
4 hours ago
- Business Wire
CEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline
VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American: CVM) today announced that a Breakthrough Medicine Designation application has been filed with the Saudi Food and Drug Authority (SFDA) for Multikine* (Leukocyte Interleukin, Injection) in the Kingdom of Saudi Arabia by one of the Kingdom's premier pharmaceutical and healthcare companies. CEL-SCI has signed a Memorandum of Understanding (MOU) with this Saudi pharma company for the commercialization of Multikine in Saudi Arabia. A final partnership agreement is expected during the 3 rd quarter of 2025. Multikine is a cancer immunotherapy administered before surgery as a treatment for newly diagnosed previously untreated head and neck cancer. Its goal is to activate a person's immune system to fight cancer before the ravages of surgery, radiation and chemotherapy have weakened the immune system. In the world's largest head and neck cancer Phase 3 study, Multikine increased the 5-year survival rate of the target patient population to 73% vs 45% in patients treated with standard of care alone and halved the risk of death from 55% to 27%. According to the SFDA, the response time to a Breakthrough Medicine Designation application is approximately 60 days. Following the granting of Breakthrough Medicine Designation, Multikine would immediately become available for patient access and reimbursement/sale in Saudi Arabia. The Saudi pharma company is well positioned to procure reimbursement and to accelerate Multikine's sale and commercial launch. Several leading Saudi funds have expressed interest in investing in Multikine, CEL-SCI, and a potential joint venture to serve the wider Middle East and North Africa (MENA) market. CEL-SCI is working closely with First Berlin of Germany and its Saudi representatives to advance its commercialization program for Multikine. Martin Bailey, Managing Director and Founder of First Berlin, the lead advisor, commented, 'CEL-SCI's prospective new partner is a prominent and innovative leader that has rendered many valuable healthcare services to the Kingdom. The Saudi pharma company's keen interest in Multikine to make patients' first cancer treatment more curative is very much in line with their forward-thinking approach and fits well with Saudi Arabia's Vision 2030 and the National Biotechnology Strategy. We look forward to facilitating the signing of a final partnership agreement and making Multikine available to patients as quickly as possible.' 'This MOU and the filing for Breakthrough Medicine Designation mark a significant advancement for Multikine's global regulatory, patient access/sale and commercial roll out,' stated CEL-SCI CEO, Geert Kersten. 'We've had a highly productive working relationship with this prestigious Saudi pharma company, First Berlin, and the SFDA and hope to see Multikine improve longevity and well-being for head and neck cancer patients in Saudi Arabia.' About the SFDA's Breakthrough Medicine Program The SFDA Breakthrough Medicine Program aims to facilitate and accelerate development and review of new drugs that address unmet medical needs in the treatment of serious or life-threatening conditions in alignment with Saudi Arabia's Vision 2030 initiative. The program is voluntary and based on early dialogue with drug developers to optimize development plans and speed up evaluation. The goal is to ensure that promising medicines are available as soon as it can be concluded that the medicines' benefits justify their risks. Eligibility includes having to fulfill all of the following four criteria in order to gain a Breakthrough Medicine Designation: Target serious debilitating or life-threatening conditions with unmet medical need. The medicinal product is likely to offer major advantages over methods currently used. The potential adverse effects of the medicinal product are considered to be outweighed by the benefits, allowing for the reasonable expectation of a positive benefit/risk balance. The product is not registered at any regulatory authority at the time of submission of the designation request. About CEL-SCI Corporation CEL-SCI believes that boosting a patient's immune system before surgery, radiotherapy and chemotherapy have damaged it, should provide the greatest possible impact on survival. Multikine is designed to help the immune system "target" the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. Multikine (Leukocyte Interleukin, Injection), given right after diagnosis and before surgery, has been dosed in over 740 patients and received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck. The Company has operations in Vienna, Virginia, and near/in Baltimore, Maryland. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital, inability to finalize a partnering agreement and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2024. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. * Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy. This proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.
Geek Wire
a day ago
- Geek Wire
Worldcon 2025 celebrates the past and future of science fiction — and the part Seattle has played
Geek Life: Fun stories, memes, humor and other random items at the intersection of tech, science, business and culture. SEE MORE Thousands of science fiction and fantasy fans will be going back to the future this week when Seattle plays host to Worldcon, the world's premier sci-fi convention, for the first time since the Space Needle opened its doors. 'The Pacific Northwest is a great community of makers and doers and learners, and people really deeply engaged in speculative fiction and all that genre has to offer,' Kathy Bond, the chair of Seattle Worldcon 2025, told GeekWire. 'We want to share that with the rest of our world community.' Registered Worldcon members selected the site of the annual convention under the auspices of the World Science Fiction Society — a tradition that started with the first convention in New York City in 1939. Seattle's organizers have been preparing for this week since 2017, when they sent in their initial bid to host Worldcon. Bond, a volunteer who works as an attorney at her day job, became involved after attending her first Worldcon in 2015 in Spokane. 'From there, I got it into my head that we could totally do this in Seattle,' Bond said. The path hasn't always been smooth: This spring, a controversy arose over the revelation that generative AI was used to glean information about prospective speakers. Bond issued an apology, and the organizers reworked the process for vetting Worldcon's panelists — but the episode led some writers and fans to create a one-day alternative convention called ConCurrent Seattle, set for Thursday. 'The goal is to provide quality programming that rejects the use of genAI at all levels,' ConCurrent's organizers said. 'We firmly believe there is no place for genAI when it has been used to steal from artists and has a devastating impact upon the environment.' Headliners and the Hugos Worldcon's five-day program kicks off on Wednesday. This year's best-known featured guest is Martha Wells, the author of the Murderbot Diaries, a series of tales about a conflicted killer robot. 'With the Apple TV+ adaptation, the timing has worked out really well for her appearance here,' Bond said. Other guests of honor include sci-fi / fantasy artist Donato Giancola, rocket scientist Bridget Landry and folk minstrel Alexander James Adams. The convention's hosts are sci-fi authors K. Tempest Bradford and Nisi Shawl. George R.R. Martin, the writer whose novels inspired the 'Game of Thrones' and 'House of the Dragon' TV series, is among more than 800 panelists who have signed up to talk about topics ranging from generative AI and surveillance tech to the joys of Star Trek fanfic and tips for creating the perfect costume. You can expect a heady swirl of cosplay, particularly when the Worldcon masquerade takes place on Friday night. The convention reaches a climax on Saturday night when the annual Hugo Awards are handed out. But if you take a wider perspective, the Pacific Northwest and its science-fiction legacy could well be considered the stars of the show. Worldcon's organizers are leaning into the fact that the last time the convention came to the Emerald City, in 1961, the Seattle World's Fair (a.k.a. the Century 21 Exposition) was just seven months away from its opening in 1962. Promotional materials for this year's Worldcon reflect an appropriately '60s-style retro-futuristic look. The theme for the convention is 'Building Yesterday's Future — For Everyone.' Qne of this week's panel sessions will take a long look back at Century 21 and assess how close the fair's techno-optimistic vision of the future came to 21st-century reality. During the past six decades, the timelines for Seattle's tech history and science fiction's progress have become closely entangled, said Frank Catalano, a journalist, former tech executive and self-described 'minor science-fiction author' who is participating in three Worldcon panels this week. Catalano's résumé includes a stint as a GeekWire contributor — and he's also been the secretary of the Science Fiction and Fantasy Writers Association as well as a member of the administrative team for SFWA's Nebula Awards. He has vivid memories of Seattle's science-fiction scene during its heyday. 'It was amazing to me, even back in the 1980s, what a rich group of speculative-fiction writers lived here,' Catalano said. 'You had Frank Herbert, you had Vonda McIntyre and Greg Bear. Octavia Butler moved here in the 1990s. Terry Brooks, the fantasy writer, is in this area. So, you have some of what are considered now the greats of science fiction and fantasy living in this area and stimulating other writers.' One of Vonda McIntyre's contributions, beyond her sci-fi novels and short stories, was her role as the founder of Seattle's Clarion West Writers Workshop in 1971. Hundreds of writers have gone through Clarion West's summer workshop, under the tutelage of some of the best-known names in speculative fiction. The future of science fiction and tech Catalano argues that science fiction had a hand in making Seattle into the tech powerhouse it is today, with the late Microsoft co-founder Paul Allen serving as a prime example. 'I'm sure that Paul Allen, were he still alive, would admit that he was inspired by many of the same people whose artifacts he later wound up exhibiting in the Science Fiction and Fantasy Hall of Fame,' he said. 'The science-fiction presence in the greater Seattle area is not because of the tech industry and economy. It stimulated and was a precursor to that.' Catalano isn't so sure that Seattle's current cultural environment is as conducive to fostering the science-fiction community. 'Amazon and Microsoft and the other tech gorillas tend to suck all the speculative air out of the room,' he said. 'People are more interested in talking about the latest hype about AI and intelligent assistants than they are in speculating about the future and what these things might do.' That's where Worldcon could provide a boost. 'My hope is that with Worldcon here, and with the attention that gets, it will help raise the profile of science fiction, fantasy, horror writing and related speculative writing in the area, and maybe help writers find each other and re-create a stronger community here,' Catalano said. Convention chair Kathy Bond is on the same page. 'I've been thinking a lot about 'why this.' Why am I asking people to spend their money on coming to Worldcon when they could be donating their money to bail funds, or donating their money to Gaza, or all of these other things?' she said. 'The answer I've come to is that art is still really important,' Bond said. 'We need our fiction, particularly our speculative fiction, because it helps us build better futures and aspire to be better than we are currently. These spaces that we create for the community to come together and celebrate what's already there, and challenge each other to come up with new ideas and new ways to try to build better futures … I think that's really important.' Seattle Worldcon 2025 runs from Wednesday to Sunday, with most events taking place at the Seattle Convention Center's Summit building. Membership rates for attendees range from $75 to $500 for the full convention, and $20 to $70 for single-day attendance. Check the Worldcon website for details. ConCurrent Seattle offers a full day of panels on Thursday at the ACT Theatre / Union Arts Center. Admission is free, but registration is required. To hear more about Worldcon and the state of the science-fiction community, check out this week's Fiction Science podcast. Alan Boyle and science-fiction author Dominica Phetteplace chat with Tim Chawaga about his newly published climate-fiction novel, 'Salvagia,' and also discuss what's happening at Worldcon. Chawaga will do a book reading and participate in two panels at Worldcon this week, while Phetteplace will talk about the outer solar system with astronomer Pedro Bernardinelli of the University of Washington's DiRAC Institute.
